Barclays raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $95 from $80 and keeps an Overweight rating on the shares. The company reported a second consecutive beat quarter for Tryngolza and raised 2025 revenue guidance, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- Ionis Pharmaceuticals: Strong Q3 Performance and Promising Pipeline Drive Buy Rating
- Ionis Pharmaceuticals Reports Strong Q3 2025 Growth
- Ionis Pharmaceuticals Shines in Q3 2025 Earnings Call
- Ionis Pharmaceuticals: Strong Growth Potential and Strategic Advancements Drive Buy Rating
- Ionis Pharmaceuticals: A Compelling Buy with Strong Performance and Promising Growth Catalysts